Drug Profile
Sodium thiosulfate - Decibel Therapeutics
Alternative Names: DB-020Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Decibel Therapeutics
- Class Antidotes; Antituberculars; Chemoprotectants; Thiosulfates; Vasodilators
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Sensorineural hearing loss
Most Recent Events
- 25 Sep 2023 Decibel Therapeutics has been acquired by Regeneron Pharmaceuticals
- 11 Aug 2023 Sodium thiosulfate receives Breakthrough Therapy status for Sensorineural hearing loss in USA
- 11 Aug 2023 Updated safety data from a phase Ib trial in Sensorineural hearing loss released by Decibel Therapeutics